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Autosomal dominant polycystic kidney disease (ADPKD), the
most common inherited cause of kidney failure, is causedbymuta-
tions in either PKD1 (85%) or PKD2 (15%). The PKD2 protein,
polycystin-2 (PC2orTRPP2), is amemberof the transient receptor
potential (TRP) superfamily and functions as a non-selective cal-
cium channel. PC2 has been found to form oligomers in native
tissues suggesting that it may form functional homo- or heterotet-
ramers with other subunits, similar to other TRP channels. Our
experimentsunexpectedlyrevealedthatPC2mutantproteins lack-
ing the known C-terminal dimerization domain were still able to
formoligomersandco-immunoprecipitate full-lengthPC2, imply-
ing the possible existence of a proximal dimerization domain.
Using yeast two-hybrid and biochemical assays, we have mapped
an alternative dimerization domain to the N terminus of PC2
(NT2-1-223, L224X). Functional characterization of this domain
demonstrated that it was sufficient to induce cyst formation in
zebrafish embryos and inhibit PC2 surface currents in mIMCD3
cells probably by a dominant-negative mechanism. In summary,
we propose a model for PC2 assembly as a functional tetramer
which depends on both C- andN-terminal dimerization domains.
These results have significant implications for our understanding
ofPC2 functionanddiseasepathogenesis inADPKDandprovide a
new strategy for studying PC2 function.
Autosomal dominant polycystic kidney disease (ADPKD),3
the most common inherited human renal disease, has been
shown to result from mutations in either PKD1 or PKD2 (1).
ADPKD accounts for 10% of patients on renal replacement
therapy and is therefore an important cause of end-stage renal
failure world-wide. The cardinal feature of the ADPKD kidney
is the presence ofmultiple fluid-filled cysts. However, cysts also
arise in other epithelial structures such as the liver and pan-
creas. A number of non-cystic manifestations such as cardiac
valve abnormalities, diverticular disease, and intracranial aneu-
rysms have been reported (2).
Mutations in PKD2 account for 15% of all patients with
ADPKD. The PKD2 protein, polycystin-2 (PC2), is a Type II
membrane protein of 968 amino acids in length (3). PC2 has the
properties of a high-conductance nonselective Ca2-permea-
ble cation channel. Because of significant homology, PC2 (or
TRPP2) has been included in the TRP (transient receptor
potential) superfamily of channels, which broadly function as
cellular sensors for multiple stimuli (4, 5). There is evidence
that PC2 may transduce a mechanosensitive Ca2 current in
primary cilia (6) although it is unclear whether the mech-
anosensor is PC1, PC2, or another protein. However, it has also
been reported that PC2 can function downstream of G protein-
coupled receptor and/or receptor-tyrosine kinase activation at
the cell surface (7–9). The basolateral localization of PC2 in
kidney tubules and cells has implicated a possible role in cell-
cell or cell-matrix adhesion in association with PC1 (10, 11).
Finally, it has been reported that PC2 can function as an endo-
plasmic reticulum-located Ca2 release channel in some sys-
tems (12).
Previously we demonstrated that PC2 can exist as PC1-PC2
heterodimers as well as PC2 homodimers in native tissues (10).
Interactions between PC1 and PC2 may regulate their traffick-
ing and there is evidence for reciprocal activation or inhibition
of activity in different experimental systems (13, 14). PC2 may
also heterodimerize with TRPC1 through its C terminus (5, 9).
PC2-TRPC1 heteromultimers have been shown to possess dis-
tinct channel properties from PC1-PC2 heterodimers, being
activated in response to G protein-coupled receptor activation
in the kidney epithelial cell line, mIMCD3 (9). In yeast two-
hybrid assays, PC2 can homodimerize via a C-terminal domain,
which is distinct fromheterodimerization sequences for PC1 or
TRPC1 interactions (5, 15). In this report, we describe the iden-
tification and functional characterization of a second dimeriza-
tion domain for PC2within theN terminus and propose a likely
homotetrameric model for PC2 based on C- and N-terminal
interactions.
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EXPERIMENTAL PROCEDURES
Materials—All chemicals were purchased from Sigma unless
otherwise stated. Yeast vectors pGBAD-B and pACT2-B were
obtained from D. Markie (University of Otago, NZ) (16). The
plasmids LDR and CF used for the FKBP-FRB dimerization
system were gifts of T. Meyer (Stanford University) (17).
Generation of PKD2 Plasmids—Unless otherwise stated, the
PKD2 plasmids used in this work have been previously reported
(18, 19). N-terminal HA-tagged full-length and mutant
(L703X) PKD2 constructs were created by replacing an XbaI
and SacII fragment of a wild-type PKD2 plasmid (gift of S
Somlo, Yale University) with the same fragment excised from
the previously describedHA-L224Xplasmid (19). AC-terminal
HA-tagged PKD2 mutant construct, R742X, was generated by
PCR using the wild-type PKD2Pk plasmid as a template includ-
ing theHAepitope tag sequence and in-frame stop codon in the
reverse primer. Themissense PKD2mutation, D511V, was cre-
ated by site-directed mutagenesis in the PKD2Pk plasmid tem-
plate using a previously published protocol (19). The N-termi-
nal Myc-tagged L224X plasmid was generated by PCR and
subcloned into the XbaI and HindIII sites of pcDNA3.1 ().
The plasmids CFP-PKD2-(1–177) and CFP-PKD2-(1–223)
were generated by fusing the N-terminal sequences of PKD2
in-frame with the CFP and FKBP cassette in the vector, CF.
Immunoblotting and Immunoprecipitation—HEK-293 and
mIMCD3 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum. Transient
transfectionwas carried out on cells cultured to 90% confluency
using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Immunoblotting and immunoprecipita-
tion (IP) was performed as previously described using epitope-
specific antibodies (10). The PKD2 antibody, p30, generated to
the C-terminal 258 amino acids of human PC2, has been previ-
ously reported (18).
Yeast Two-hybridAssays—Yeast two-hybrid assayswere per-
formed in the yeast strain AH109 containing ADE2, HIS3, and
LacZ reporter genes under the control of the GAL4 upstream
activating sequences (UAS) by co-transforming bait and prey
constructs of the entire intracellular N terminus of human PC2
(NT2) or its truncations into yeast cells using a published pro-
tocol (20). Full-length NT2-(1–223) was subcloned into bait
(BD) vector pGBKT7 and prey (AD) vector pGADT7 (Clon-
tech), respectively, by PCR and DNA ligation. Similarly, the
following NT2 truncations, NT2-(1–207), NT2-(1–198), NT2-
(1–177), NT2-(1–117), NT2-(1–61), andNT2-(178–223) were
constructed in both bait and prey vectors. After incubation at
30 °C for 3–4 days, positive co-transformants (containing both
bait and prey plasmids) were picked from selective medium
S.D./-LT (lacking tryptophan and leucine) and restreaked onto
selective media S.D./-LTH (lacking tryptophan, leucine, and
histidine), S.D./-LTH with 2 mM 3-amino-1,2,4-triazole
(3-AT), and S.D./-LTAH (lacking tryptophan, leucine, histi-
dine, and adenine), respectively, to activate the reporter genes
HIS3 and ADE2. 2 mM 3-AT was used in the selective medium
to suppressminor autoactivation ofNT2-(1–198) andNT2-(1–
177) in the pGBKT7 vector. The constructs pGBKT7–53 (p53)
and pGBADT7-T (SV40 T-antigen) were used as a pair of pos-
itive controls. Truncations of the PC2 C terminus (CT2) and
PC1 C terminus (CT1), which mimic two naturally occurring
mutants lacking their respective interaction domains i.e. PKD2-
R742X and PKD1-R4227X, respectively, were generated as a
pair of negative controls: pGBAD-B-CT1 (4107–4227) and
pACT2-B-CT2 (680–742). At least three individual colonies
were chosen from each plate to quantify growth.
Live Cell Imaging—IMCD3 and HEK-293 cells were tran-
siently transfected using Lipofectamine 2000 (Invitrogen) with
the following cDNAs: CFP-FKBP-L223 (CF-PKD2–223), CFP-
FKBP-L177 (CF-PKD2–177), and Lyn11-FRB (LDR). Translo-
cation of the fusion proteins to the cell surfacewas induced 24 h
later by the addition of 10 M rapamycin (Calbiochem) to the
culture media. In some experiments, co-expression of a sur-
face-localized YFP fusion protein (C1 domain of PKC-1,
YFP-C1 (PKC)) was used to outline the plasmamembrane. Live
cell measurements were performed on an Olympus Imaging
Systems inverted IX-71 microscope with a CFP and YFP filter
set to capture cellular fluorescence images with a CCD camera
(Hamamatsu), driven by Simple PCI software (C Imaging Sys-
tems). Fluorescence images of cells were taken every 5 s at room
temperature. Changes in themean fluorescence intensity over a
given region of the cytosol and nucleus were quantified in indi-
vidual cells (n 6) using ImageJ (NIH) (21).
Electrophysiology—The whole cell voltage-clamp configura-
tion was used in the perforated mode to measure transmem-
brane currents in single cells. Briefly, patch-clamp recordings
were obtained from single cells at 37 °C using a Warner
PC-505B amplifier (Warner Instrument Corp., Hamden, CT)
and pClamp 8 software (Axon Instrument, Foster City, CA).
Glass pipettes (plain, Fisher Scientific) with resistances of 5–8
M were prepared with a pipette puller and polisher (PP-830
and MF-830, respectively, Narishige, Tokyo, Japan). After the
whole cell configuration was achieved, cell capacitance and
series resistance were compensated before each recording
period. Current measurements in time course experiments
weremade by applying a 100-ms pulse from a holding potential
60 mV to100 every 10 s for 5 min. Current amplitude was
extracted at100mVandplotted as function of time (min). I-V
curves were derived from a voltage step protocol as follows:
from a holding potential of60mV, voltage steps were applied
from100 to 100 mV in 20-mV increments with 200 ms dura-
tion at 3-s intervals. Current traces were filtered at 1 kHz and
analyzed off-line with pClamp 8. Statistical analysis was
employed with the SigmaStat (Chicago, IL) software. Data were
reported as means S.E. Student’s t test was used for compar-
isons between groups. Differences were considered significant
at p  0.05. The pipette solution contained (in mM): 0.3
Amphotericin B, 110 potassium aspartate, 30 KCl, and 5
HEPES, pH 7.2. The bath solution contained (in mM): 130 KCl,
1 MgCl2, 10 HEPES, 0.1 CaCl2, and 5 glucose (pH 7.4).
Zebrafish Experiments—Wild-type zebrafishAB strainswere
maintained and staged according to standard protocols (22).
Embryos were treated with 0.003% 1-phenyl-2-thiourea
(Sigma) in 0.5 E2 solution to reduce pigmentation. At the
one-cell stage, embryos weremicroinjected with pkd2ATGMO
or controlMO (GeneTools LLC) to block zebrafish pkd2 trans-
lation as described (23) at finalMOconcentrations estimated at
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100 nM. In vitro-transcribed capped mRNA encoding human
PKD2-L177, -L223, and D511V were synthesized using a
mMessagemMachineT7 kit (Ambion), and 50 pgwere injected
or co-injected at the one-cell stage. Injection solution condi-
tions have been described in a previous report (19).
RT-PCR—Total RNA was isolated from 48 hpf embryos by
using the RNAqueous-4PCR Kit (Ambion). Nested RT-PCR
primers were designed from human PKD2 sequence to confirm
expression in zebrafish embryos. RT-PCRwas performed using
the SuperScriptTM III One-Step RT-PCR System with Plati-
numTaqHigh Fidelity (Invitrogen) followed by a second PCR
using PhusionTM High-Fidelity DNA Polymerase (New Eng-
landBioLabs). Amplification of-actinwas performed as a pos-
itive control. The human PKD2 primers used were: 148F1:
GGCCTGGAGATCGAGATG, 332R1: ACCACCATTCCGC-
CTTCT, 149F2: GCCTGGAGATCGAGATGC, 320R2: CCT-
TCTTCCCCTTCCACCT. All procedures involving kits were
performed according to the manufacturers’ protocols.
Immunohistochemistry—Whole zebrafish embryos were
fixed in 100% MeOH at 4 °C overnight. After rehydration,
embryos were washed in PBS plus 0.5% Triton X-100 and
blocked in PBS-DTR (PBS plus 1% DMSO, and 0.5% Triton
X-100) with 10% normal goat serum (NGS) at room tempera-
ture for 1 h. Anti-polycystin-2 (1:800; gift of I. Drummond) (24)
was incubated in PBS-DTR 2% NGS for 4 °C overnight.
Embryos were washed in PBTX (PBS/0.5% Triton X-100) for
2 h and then incubated in 1:1000 CY3-labeled goat anti-rabbit
IgG (Jackson ImmunoResearch) in PBS-DTR 2X NGS at room
temperature for 2 h. After rinsing the embryos in PBTX for 2 h,
they were dehydrated, embedded in JB-4 (Polyscience), and
sectioned at 10-m thickness. Sections were stained with
1:1000DAPI (KPL) solution for 3min at room temperature, the
slides rinsed once with PBS and thenmounted with fluorescent
mounting medium (KPL). Section images were taken using a
Nikon E500 microscope and analyzed by the Spot v. 4.4
program.
Histochemistry—48-days postfertilization (dpf) embryos
were fixed in 1.5% glutaraldehyde (Electron Microscopy Sci-
ences), 1% paraformaldehyde (Electron Microscopy Sciences),
70mMNaPO4 pH7.4, 3% sucrose at 4 °C overnight, dehydrated,
embedded in glycolmethacrylate (JB4; Polyscience), and sec-
tioned at 4-m thickness using HM325 (Richard-Allan Scien-
tific). Slideswere stainedwith hematoxylin and eosin (BBCBio-
chemical) according to the protocol from Jennifer R. Panizzi
and Lilianna Solnica-Krezel.4
RESULTS
Evidence for a Second Dimerization Domain in PKD2—We
initially generated three naturally occurring PKD2 mutants,
one with a single missense change in the third transmembrane
domain (D511V) and two others lacking the C-terminal
homodimerization domain, L703X and R742X (Fig. 1). The
D511V mutation has previously been shown to completely
abolish PC2 channel activity whereas L703X and R742X have
altered channel properties in some expression systems (12, 25).
Relevant to the present study, D511Vhas been demonstrated to
function as a dominant negative interfering allele in mIMCD3
(9) and LLC-PK1 cells (26). As previously shown for endoge-
nous PC2 (10), full-length PKD2 could be detected mainly as
monomers under normal reducing conditions on SDS-PAGE
but as oligomers under non-reducing conditions (Fig. 2A).
Apart from prominent dimers, several other high molecular
weight bands were detected under non-reducing conditions.
These could represent homophilic binding between PC2 sub-
units or heterophilic interactions with other proteins. PKD2-
D511V, showed a similar pattern of oligomerization under
these conditions (data not shown). Unexpectedly we found that
PKD2-L703X, could still form dimers under non-reducing con-
ditions (Fig. 2A). Similar results were found for PKD2-R742X
(not shown). As predicted, PKD2-D511V bound to wild-type
PKD2, but unexpectedly, so did PKD2-R742X in co-immuno-
precipitation (co-IP) assays (Fig. 2, B and C). To exclude the
effect of the epitope tags in the interaction, we repeated these
experiments with different PKD2 full-length (Myc-tagged) and
mutant (C-terminal HA-tagged) constructs and obtained sim-
ilar results (data not shown). We therefore hypothesized that a
proximal interacting domain could lie upstream of the previ-
ously described distal C-terminal domain, possibly in the N
terminus. Indeed, the isolated PC2 N-terminal domain (NT2-
(1–223)) could interact with itself in HEK293 cells (Fig. 2D).
Defining the Dimerization Domain using Yeast Two-hybrid
Assays—To characterize and refine this domain further, yeast
two-hybrid assays were performed. As shown in Fig. 3, yeast
co-transformants containingNT2-(1–223)-pGBKT7 (bait) and
NT2-(1–223)-pGADT7 (prey) were able to grow on selective
media requiring the activation of two reporters i.e. HIS3 and
ADE2. NT2 did not interact with the C terminus of PC2 (CT2,
data not shown). Further studies were carried out to refine the
minimal interacting region using deletion constructs. As
showed in Fig. 3, the truncation NT2-(1–207) could still inter-
act with NT2-(1–223), while truncations NT2-(1–177) and
NT2-(1–198) lost the ability to interact with NT2-(1–223).
Shorter sequences of NT2 such as NT2-(1–61) and NT2-(1–4 Personal communication.
FIGURE 1. Schematic diagramof epitope-taggedPKD2 constructs used in
the studywith their predicted domains. Apart fromwild-type PKD2, a site-
specific mutant (D511V), two mutants with truncations of the C terminus
(R742X and L703X), and the isolated N-terminal domain (L224X) were gener-
ated for study.
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117) were unable to interact with full-length NT2-(1–223) (not
shown). These results indicate that the region from codons
199–207 is an essential part of the N-terminal interacting
domain. The sequence NT2-(178–223) showed a weaker inter-
action than NT2-(1–223) in our assay (data not shown) sug-
gesting that flanking sequences might be important in deter-
mining binding affinity. Fig. 3C shows the high sequence
conservation of this region between human, mouse, and
zebrafish PC2. Between codons 190 and 207, 12 of 17 amino
acids (70.6%) are identical or similar compared with human/
mouse PC2. This contrasts with the minimal sequence conser-
vation between human and zebrafish PC2 in the preceding
sequence of NT2 (codons 119–189).
Induction of Zebrafish Pronephric Cyst Formation by Co-in-
jection of PKD2-L223 mRNA—We have previously established
the zebrafish as a relevant model system to study human
ADPKD (19, 24). Disruption of zebrafish pkd2 expression with
morpholinos (MO) results in cyst formation in the glomerulus
and pronephric tubules in conjunction with changes in body
axis curvature and hydrocephalus. All of these features were
rescued by co-injection of human PKD2 mRNA (19, 24).
Because of sequence conservation between humans and
zebrafish, we reasoned that the zebrafish model could be used
to test the functionality of the N-terminal domain of PC2 by a
dominant negative mechanism. These results are summarized
in Table 1. To establish if a dominant negative effect could be
FIGURE2.Biochemical evidence for aproximaldimerization sequence in theN terminusofPC2.A, detectionof epitope-taggedwild-typeandmutant PC2
expressed in HEK293 cells by immunoblotting under reducing (R) and non-reducing (NR) conditions in three individual samples. Note that both forms of PC2
aredetectedpredominantly asmonomers under reducing SDS-PAGEbut that there areprominent slowermigrating species visible under non-reducing states.
For full-length PC2, apart from prominent dimeric species (220 kDa), there are also higher bands suggestive of more complex oligomeric structures (e.g.
tetramers). For L703X, the monomeric species are more notable than for wild-type PC2 under NR conditions but there is also detectable dimer formation
(150kDa). Calnexin was used as an endogenous control for loading. * indicates a minor nonspecific band detected by the HA antibody. B, coimmunopre-
cipitation of epitope-tagged PC2-D511V (D511VPk) and wild-type PC2 (HA-PKD2). PC2-D511V is predicted to retain both hetero- and homodimerization
C-terminal domains. C, PC2 mutant lacking both C-terminal dimerization domains (HA PKD2 R742X) associates with wild-type PC2 (PKD2Pk). The p30 and pK
antibodies only recognize C-terminal epitope in full-length PC2. However, the HA antibody, which only recognizes the mutant R742X was able to co-IP
wild-type PC2 (PKD2Pk) suggesting an interacting sequence proximal to the truncation. 1 mg of total cell lysate was used for IP with HA or NIS (non-immune
serum) and 0.1 mg (1/10) for IP with p30 as indicated. 30 g of lysate were loaded as a positive control. The converse experiment showed that p30 or pK
antibodies could pull-down R742X. D, co-immunoprecipitation of HA-tagged N-terminal PC2 protein (NT2) containing the first 223 amino acids (L224X) with
co-expressed Myc-tagged L224X. These results implied the existence of an N-terminal dimerization domain.
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observed in this system, we initially tested the effect of injecting
human PKD2-D511V synthetic mRNA into one-cell stage
zebrafish embryos. Injection of human PKD2-D511V synthetic
mRNA alone (Fig. 4E) induced the
same phenotypic changes seen in
pkd2ATGMO-injected embryos
(Fig. 4D). Moreover, as shown in
Fig. 4, co-injection of PKD2-D511V
mRNA with pkd2ATGMO could
not rescue the pkd2ATGMO
induced phenotype (Fig. 4F) unlike
wild-type PKD2 mRNA. Therefore,
these results established a a domi-
nant negative mechanism for
PKD2-D511V in zebrafish and fully
supported previous data using the
same construct in mIMCD3 cells
(9).
Next, we injected PKD2-L223 in
zebrafish embryos and tested
whether it could result in a
phenotype similar to the pheno-
type obtained by injection of
pkd2ATGMOorPKD2-D511V. Fig.
4C shows that PKD2-L223 induced
body axis curvature, pronephric
cyst formation and hydrocephalus
whereas injection of human PKD2-
L177 mRNA lacking the dimeriza-
tion domain did not (Fig. 4B). All
injected embryos with PKD2-L177
exhibited normal histology as com-
pared with embryos injected with
control MO (Fig. 4A). Expression
levels of PKD2-D511V, PKD2-L223
and PKD2-L177 were shown to be
equivalent in injected embryos by
nested RT-PCR using human-spe-
cific primers (Fig. 4G). In summary,
these data suggest that PKD2-L223
must have interfered with wild-type
PC2 and/or its interacting partners.
However, because the N-terminal
domain of PC2 has been shown not
to interact with known C-terminal
binding partners such as PKD1 or
TRPC1, it is highly likely thatPKD2-
L223 mediated its effect by direct binding to wild-type PKD2.
Embryos injected with either PKD2-D511V (Fig. 4E) or
PKD2-L223 (Fig. 4C) mRNA all showed a reduction of endog-
enous zebrafish PC2 expression similar to that seen with
pkd2ATGMO (Fig. 4D). These results raised the possibility that
PKD2-D511V or PKD2-L223 may have bound to wild-type
PKD2 and/or marked it for degradation. An alternative possi-
bility was that the acute binding of the mutant protein could
have directly inhibited surface channel activity resulting in
cysts with degradation occurring as a later event.
Inducible Translocation of PKD2-(223) to the Plasma Mem-
brane Inhibits Endogenous and Transfected PKD2 Surface
Currents—To address whether PKD2-1–223 could acutely
inhibit surface PC2 channels, we exploited a novel ligand-in-
FIGURE 3. Dimerization of the polycystin-2 N terminus (NT2) detected by yeast two-hybrid assays.
A, growth of yeast co-transformants cultured on selective media S.D./-LTH with 2 mM 3-AT and S.D./-LTAH to
activate HIS3 and ADE2 selectionmarkers, respectively. The pairs of NT2 sequences tested are numbered from
1–4 and their sequences indicated. Constructs pGBKT7–53 (p53) and pGBADT7-T (SV40-T antigen) were used
as a pair of positive controls while pGBAD-B-CT1 (4107–4227) and pACT2-B-CT2 (680–742) were used as a pair
of negative controls. B, truncations of the N terminus of polycystin-2 (NT2) marked by the number of starting
and ending amino acid residue and their interactionwithNT2. The fragments on the left column are in bait (BD)
constructs, while the fragments in the right column are in prey (AD) constructs. The numbers in the left column
indicate the pairs of NT2 constructs tested and correspond to those shown in A. Positive (interaction) and
negative results are indicated by , , , and  for the appearance of positive growth on selective
medium within 24 h, 48 h, and 3–7 days or no positive growth in 2 weeks, respectively. C, multiple sequence
alignment of PC2orthologues fromdifferent species overlappingwith the sequenceof humanNT2-(190–238).
Amino acids which show perfect conservation down to zebrafish are indicated by an asterisk (*) in the bottom
line. In the region between amino acids 190 and 223, 23 of 33 amino acids (70%) are identical or similar. This
contrasts with the region between amino acids 119 and 189 where only 1 of 70 amino acids (1.4%) show
identity from human to Danio. The accession numbers for each sequence are as follows: Q13563 (Homo sapi-
ens), O35245 (Mus musculus), Q4GZT3 (Bos taurus), Q5ZM00 (Gallus gallus), and Q6IVV8 (Danio rerio).
TABLE 1
Zebrafish phenotypes after injection of capped PKD2mRNA and/or
pkd2morpholino at the one-cell embryo stage
Total embryos
injected
Normal
embryos
Cysts and body
axis curvature
A. Control MO 303 303 (100%) 0 (0%)
B. Human PKD2-L177 254 250 (98%) 4 (2%)
C. Human PKD2-L223 252 20 (8%) 232 (92%)
D. pkd2ATGMO 222 12 (5%) 210 (95%)
E. Human PKD2-D511V 296 6 (5%) 281 (95%)
F. pkd2ATGMO human
PKD2-D511V
103 2 (2%) 101 (98%)
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duced (rapamycin) chemical dimerization system (summarized
in Fig. 5F) based on the rapamycin-induced dimerization
between FKBP and FRB (17). The FRB (FKBP-rapamycin bind-
ing) domain was fused to a plasma membrane targeting
sequence of the Rho GTPase Lyn (LDR) while CFP-tagged
FKBP (FK506- and rapamycin-binding protein) was fused to
the N terminus of PKD2-(1–223) to generate CF-PKD2-(223).
As a control, we utilized PKD2-(1–177) to generate CF-PKD2-
(177). In the absence of rapamycin, both CF-PKD2 fusions are
primarily expressed in the cytoplasm. On addition of rapamy-
cin in the presence of the FRBdomain (LDRplasmid), therewas
a rapid translocation of both fusion proteins to the plasma
membrane in HEK293 (not shown) and mIMCD3 cells (Fig. 5)
as shown by the loss of cytoplasmic CFP fluorescence in indi-
vidual cells over time. Moreover, the decrease in fluorescent
intensity (	F) over baseline intensity (F0) triggered by rapamy-
cin was significantly altered for cytosolic CFP compared with
the nuclear signal in the presence of LDR (n 6) (Fig. 5E). The
translocated CFP signal clearly overlapped with the YFP signal
of a co-expressed surface-localized protein, YFP-C1 (PKC).
The original CF (CFP-FKBP-Inp54p) construct served as a pos-
itive control (data not shown) (21).
Fig. 6 shows that addition of rapamycin induced a time-de-
pendent reduction in whole cell current amplitude ofmIMCD3
cells transiently transfected with LDRCF-PKD2-(223) cells
from23.7 0.9 pA/pF to14 0.6 pA/pF at100mV (Fig.
6,A andD). The reduction in current amplitude was significant
up to 40 mV (Fig. 6D). Rapamycin did not have an effect in
untransfected (from23.6 1.2 pA/pF to22.7 1.2 pA/pF
at 100 mV) (Fig. 6B) or LDRCF-PKD2 (177)-transfected
cells (from 23.5  1.4 pA/pF to 22.3  1.4 pA/pF at 100
mV) (Fig. 6C). It should be noted that constitutive overexpres-
sion of PKD2-D511V in these cells suppressed whole cell cur-
rents from24.3 3.4 pA/pF (n 9) to10.3 2.28 pA/pF
(n  7) under identical recording conditions (9) suggesting a
similar mechanism of whole cell current density inhibition by
PKD2-D511V or PKD2-L223. The small difference in whole
cell current density (4 pA/pF) between PKD2-D511V and
PKD2-L223 may be explained by the higher affinity of PKD2-
D511V than PKD2-L223 for binding to wild-type PKD2 or
binding of PKD2-D511V to other interacting partners of PKD2
such as TRPC1, whichwas shown to be required for basal activ-
ity of native PKD2 in these cells (9). In contrast, PKD2-L223
should not associate with PKD1 or TRPC1 (5, 15) and therefore
its effect on whole cell current density should be specific to
wild-type PKD2, at least based on existing data.
To further confirm the specificity of CF-PKD2-(223) on
PKD2, we overexpressed full-length PKD2 and tested the effect
of CF-PKD2-(177) or CF-PKD2-(223) on transfected PKD2.
Overexpression of PKD2 resulted in an increase in overall
whole cell current density from23.6 1.2 pA/pF to45.4
1.8 pA/pF at 100 mV (Fig. 6, B and F, black plot), consistent
with the formation of active channels at the plasma membrane
(9). Addition of rapamycin to the bath induced a time-depend-
ent reduction in whole cell currents in PKD2-, LDR-, and
CF-PKD2-(223)-cotransfected cells from 43.5  1 pA/pF to
21.8  1 pA/pF at 100 mV (Fig. 6H). However, in PKD2-
transfected alone (Fig. 6F) or PKD2-, LDR-, and CF-PKD2-
(177)-cotransfected cells, rapamycin did not affect whole cell
currents (Fig. 6G). These data provide direct evidence for a
dominant negative effect of CF-PKD2-(223) on native or trans-
fected PKD2 surface channel activity. In this system, binding of
PKD2-L223 resulted in acute inhibition of channel activity
because the effect was observed almost immediately following
FIGURE 4. Human PKD2-L223 and D511V induce pronephric cysts in the
zebrafish and downregulate zebrafish polycystin-2 expression. A, 48 hpf
zebrafish injectedwith a controlMOhave a normal body; histology section of
48 hpf embryos showing a glomerulus (glm) in the midline and pronephric
tubules connected to bilateral pronephric ducts. Endogenous zebrafish PC2,
detected with a specific antibody that does not cross-react with human PC2,
is distributed in the basolateral membranes and apical cilia in the anterior
pronephric ducts (see also H). B, 48-hpf human PKD2-L177 mRNA-injected
embryos show normal whole mount histology cross-section and zebrafish
PC2 expression. C, human PKD2-L223 mRNA-injected embryos showing pro-
nephric cysts, body axis curvature, and reduced zebrafish PC2 expression.
D, pkd2ATGMO-injected embryos showingpronephric cysts, body axis curva-
ture, and hydrocephalus. pkd2ATGMO blocked endogenous zebrafish pkd2
translation leading to a reduction in PC2 expression. E, human PKD2-D511V
mRNA-injectedembryos alsodevelopedbodyaxis curvature, cyst, andhydro-
cephalus. F, co-injectionof 50pgof humanPKD2-D511Vwasunable to rescue
the pkd2ATGMO phenotype and induced more severe body axis curvature,
cysts, and hydrocephalus than pkd2ATGMO alone. G, RT-PCR analysis for
human PKD2 (upper panel) and -actin (lower panel) mRNA expression.
Endogenous zebrafish PC2 expression is clearly down-regulated by co-injec-
tion of PKD2-L223 (C) and PKD2-D511V (E) mRNA to a similar level as
pkd2ATGMO (D).
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induced translocation of PKD2-
L223 to the plasma membrane.
DISCUSSION
In the present study, we have
identified and functionally charac-
terized a new dimerization domain
in the N-terminal cytosolic region
of PC2. This domain is shown to
have a physiologically relevant role
in zebrafish development as it phe-
nocopied known loss-of-function
constructs of PC2. We propose that
the identification of this domain has
important implications in type 2
ADPKD pathophysiology.
The tendency of native PC2 to
oligomerize led us initially to inves-
tigate how PC2 homodimerization
could be regulated. Unexpectedly,
we found that two naturally occur-
ring PC2mutants lacking the C-ter-
minal homodimerization domain
(L703X, R742X) could still form oli-
gomers and bind to full-length PC2
in mammalian cells. These findings
led us to demonstrate the existence
of a more proximal dimerization
domain within the N-terminal
domain and its functionality in two
assays of PC2 activity i.e. nephro-
genesis in zebrafish embryos and
channel activity in mIMCD3 cells.
These findings are compatible with
a likely dominant negative effect in
both models. Overall, our data
would support a direct acute inhib-
itory effect of the mutant protein
(PKD2-L223) on the PC2 channel
itself, which also leads to subse-
quent degradation of PC2. Recently,
it was reported that the transgenic
expression of PKD2-L703X in rats
gave rise to a cystic phenotype by an
undetermined mechanism (27). We
believe that our findings of an
N-terminal dimerization domain
support a dominant negative mech-
anism as a plausible explanation of
the phenotype in this model.
The existence of both N- and
C-terminal dimerization domains
in PC2 provide supportive evidence
that PC2 is likely to form functional
homotetramers, a possible model is
shown in Fig. 7. Thismodel does not
require the binding of PC1 or that
of other TRP subunits (such as
FIGURE 5. Rapamycin-induced translocation of CFP-PKD2 fusions to the plasma membrane. A–D, CFP
fluorescent images in live mIMCD3 cells co-transfected with the plasmids CF-PKD2-(177) or CF-PKD2-(223) in
the presence or absence of LDR. The left hand panels represent baseline CFP (blue), themiddle panels are CFP
signals (blue) 5–45 s following the addition of rapamycin (Rap, 10M) to themedium and the right panels, YFP
fluorescence (green) of the fusion protein, YFP-C1-(PKC), which is constitutively localized at the plasma mem-
brane. The translocation of both CFP-PKD2 fusion proteins induced by Rap in the presence of LDR can be seen
graphically by the rapid reduction in the cytoplasmic CFP signal within the time frame shown (5–45 s). In
contrast, nuclear expression of both fusion proteins is present at baseline but does not change following Rap.
E, change in cytosolic CFP fluorescence intensity (	F) expressed as a ratio of baseline CFP fluorescence (F0) was
significantly altered compared with nuclear CFP fluorescence following Rap in the presence of LDR (n  6).
F, schematic diagram of the rapamycin-induced chemical dimerization strategy used to translocate CFP-PKD2
fusions to the plasma membrane (PM). The FRB (FKBP-rapamycin binding) domain was fused to a plasma
membrane targeting sequence of the Rho GTPase Lyn (LDR), while CFP-tagged FKBP (FK506- and rapamycin-
binding protein) was fused to the N terminus of PKD2 (1–177 or 1–223) to generate CF-PKD2-(177) and
CF-PKD2-(223), respectively. Addition of Rap induces rapid heterodimerization between the PM-anchored FRB
andFKBP fusionproteins, thusbringing theCF-PKD2 fusions into closeproximityof PM-locatedPKD2channels.
N-terminal Dimerization Domain for Polycystin-2
OCTOBER 17, 2008•VOLUME 283•NUMBER 42 JOURNAL OF BIOLOGICAL CHEMISTRY 28477
 at university of sheffield on O
ctober 15, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
TRPC1) both of which have been shown to interact with PC2
via distinct sequences or amino acids in the C-terminal domain
(5). The evidence that PC2 homodimers can function inde-
pendently in vivo is indirect: PC2 can function independently of
PC1 at the embryonic node in the determination of LR asym-
metry in the axial body plan (28).
Nevertheless, an important ques-
tion is what regulates the assembly
of PC2 monomeric subunits into
homotetramers or alternatively het-
erotetramers with PC1 or other
TRP subunits. In addition, we do
not know if PC2 truncationmutants
(e.g. L703X), which retain the puta-
tive pore region and which can still
dimerize via theN-terminal domain
are still functional. In some assays,
there is evidence for altered PC2
localization (e.g. increased cell sur-
face expression) and for altered
channel properties (e.g. loss of cal-
cium responsiveness, voltage-de-
pendence) of this mutant (12, 29).
Our results also raise the possibil-
ity as to whether cyst formation in
PKD2patients could arise by a dom-
inant-negative mechanism as
shown for the D511V mutant in
addition to two-hit and haploinsuf-
ficiency models (30). If PC2 forms
an oligomeric structure, the associ-
ation of a mutant protein with wild-
type subunits would result in the generation of non-functional
multimeric complexes (Fig. 7). For a tetrameric model, poten-
tially 15 of 16 possible combinations betweenmutant and wild-
type subunits could be affected. Therefore, although there will
be 50% reduction in the wild-type protein, the reduction in
function could approximate 100%. Thismechanismwould only
be effective assuming that a stable mutant mRNA transcript
and protein are produced in patients at levels thatwould bind in
a stoichiometric fashion to wild-type monomers. Nonetheless,
given the lack of specific inhibitors to PC2, the dominant neg-
ative strategy we have described could be a useful way to study
the function of the endogenous protein in different systems.
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